title: [Both major breakthroughs and stagnation in urology. Industry, together with clinicians, are responsible for most innovations].
abstract: Urology is a specialty with many branches, including urological oncology with 25% of all cancers. Development in certain areas been very rapid, for instance with the introduction of minimally and non-invasive methods such as ESWL and phosphodiesterase inhibitors, innovations which have brought obvious improvements and have been promptly adopted in clinical practice. In other areas such as chronic abacterial prostatitis and renal cancer, progress has been very limited. Still other areas have seen useful but less spectacular improvements for which it has taken time, clinical experience and a multitude of clinical studies before they have been embraced in daily clinical practice. Examples of these more gradual developments are hyperthermia for the treatment of benign prostatic hyperplasia and transrectal ultrasound in prostate cancer.
authors: Urologkliniken, Kärnsjukhuset, Skövde. hans.hedelin@vgregion.se
authors: H
authors: H
authors: Hedelin
authors: L
authors: L
authors: Grenabo
authors: S
authors: S
authors: Holmäng
mesh_terms: D004059:Diffusion of Innovation; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D008297:Male; D013677:Medical Laboratory Science / Q000639:trends; D013678:Technology, Pharmaceutical / Q000639:trends; D014565:Urogenital Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014570:Urologic Diseases / Q000188:drug therapy* / Q000601:surgery*; D014572:Urology / Q000639:trends*